

Cefalexin Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 11474837-00005 Date of last issue: 12/08/2025
Date of first issue: 11/26/2024

SECTION 1. IDENTIFICATION

Product name : Cefalexin Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 37 McCarville Street
Charlottetown, PE C1E 2A7
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use



Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Respiratory sensitization : Sub-category 1A
Reproductive toxicity : Category 2
Specific target organ toxicity : Category 3
- single exposure
Specific target organ toxicity : Category 2 (Kidney, Adrenal gland, Blood, Gastrointestinal tract)
- repeated exposure

GHS label elements

Hazard pictograms :  

Signal Word : Danger

Hazard Statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H335 May cause respiratory irritation.
H361f Suspected of damaging fertility.
H373 May cause damage to organs (Kidney, Adrenal gland, Blood, Gastrointestinal tract) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read

Cefalexin Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 11474837-00005 Date of last issue: 12/08/2025
Date of first issue: 11/26/2024

and understood.
P260 Do not breathe mist or vapors.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves, protective clothing, eye protection and face protection.
P284 Wear respiratory protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a doctor if you feel unwell.
P308 + P313 IF exposed or concerned: Get medical attention.
P342 + P311 If experiencing respiratory symptoms: Call a doctor.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Cefalexin	No data available	15686-71-2*	>= 10 - <= 30	TSC

* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/08/2025
4.0	05/09/2026	11474837-00005	Date of first issue: 11/26/2024

- In case of eye contact : Thoroughly clean shoes before reuse.
: Flush eyes with water as a precaution.
: Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
: Get medical attention.
: Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause allergy or asthma symptoms or breathing difficulties if inhaled.
: May cause respiratory irritation.
: Suspected of damaging fertility.
: May cause damage to organs through prolonged or repeated exposure.
: Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
: Alcohol-resistant foam
: Carbon dioxide (CO₂)
: Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
: Nitrogen oxides (NO_x)
: Sulfur oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
: Use water spray to cool unopened containers.
: Remove undamaged containers from fire area if it is safe to do so.
: Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
: Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
: Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/08/2025
4.0	05/09/2026	11474837-00005	Date of first issue: 11/26/2024

- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not breathe mist or vapors.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Keep in a cool, well-ventilated place.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Gases

Cefalexin Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 11474837-00005 Date of last issue: 12/08/2025
Date of first issue: 11/26/2024

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cefalexin	15686-71-2	TWA	550 µg/m ³ (OEB 2)	Internal
Further information: RSEN				

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapor type

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Color : clear

Odor : No data available

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/08/2025
4.0	05/09/2026	11474837-00005	Date of first issue: 11/26/2024

Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics Particle size	:	Not applicable

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Cefalexin Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 11474837-00005 Date of last issue: 12/08/2025
Date of first issue: 11/26/2024

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Cefalexin:

Acute oral toxicity : LD50 (Mouse): 1,600 - 6,200 mg/kg

LD50 (Dog): > 2,000 mg/kg
Symptoms: Vomiting

LD50 (Monkey): > 1,000 mg/kg
Symptoms: Vomiting

LD50 (Rat): > 20,000 mg/kg

Acute toxicity (other routes of administration) : LD50 (Dog): > 1 g/kg
Application Route: Intraperitoneal

LD50 (Dog): > 0.1 g/kg
Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Cefalexin Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 11474837-00005 Date of last issue: 12/08/2025
Date of first issue: 11/26/2024

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cefalexin:

Assessment : Probability or evidence of high respiratory sensitization rate in humans
Remarks : Based on data from similar materials
May cause sensitization by inhalation.

Result : Sensitizer
Remarks : Based on data from similar materials
May cause sensitization by inhalation.

Germ cell mutagenicity

Not classified based on available information.

Components:

Cefalexin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging fertility.

Components:

Cefalexin:

Effects on fertility : Test Type: Two-generation study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 250 mg/kg body weight

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Cefalexin Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 11474837-00005 Date of last issue: 12/08/2025
Date of first issue: 11/26/2024

Effects on fetal development : Result: May cause adverse reproductive effects., Reduced fertility of F1 generation.
: Test Type: Development
Species: Mouse
Application Route: Oral
Embryo-fetal toxicity.: NOAEL: 400 mg/kg body weight
Remarks: No significant adverse effects were reported
Maternal toxicity observed.

Reproductive toxicity - Assessment : Test Type: Development
Species: Rat
Application Route: Oral
Embryo-fetal toxicity.: NOAEL: 1,200 mg/kg body weight
Remarks: No significant adverse effects were reported
Maternal toxicity observed.

Reproductive toxicity - Assessment : Suspected of damaging fertility.

STOT-single exposure

May cause respiratory irritation.

Components:

Cefalexin:

Routes of exposure : Inhalation
Assessment : May cause respiratory irritation.

STOT-repeated exposure

May cause damage to organs (Kidney, Adrenal gland, Blood, Gastrointestinal tract) through prolonged or repeated exposure.

Components:

Cefalexin:

Target Organs : Kidney, Adrenal gland, Blood, Gastrointestinal tract
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cefalexin:

Species : Rat
NOAEL : < 160 mg/kg
Application Route : Oral
Target Organs : Kidney, Adrenal gland, Blood
Symptoms : Vomiting, Diarrhea, Kidney disorders, Blood disorders

Species : Dog
NOAEL : < 160 mg/kg
Application Route : Oral

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Cefalexin Formulation

Version 4.0 Revision Date: 05/09/2026 SDS Number: 11474837-00005 Date of last issue: 12/08/2025
Date of first issue: 11/26/2024

|| Target Organs : Kidney, Adrenal gland, Blood
|| Symptoms : Vomiting, Diarrhea, Blood disorders, Kidney disorders

|| Species : Monkey
|| NOAEL : < 160 mg/kg
|| Application Route : Oral
|| Target Organs : Kidney, Adrenal gland, Blood
|| Symptoms : Vomiting, Diarrhea, Blood disorders, Kidney disorders

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Cefalexin:

|| Inhalation : Target Organs: Respiratory Tract
Remarks: May cause irritation of respiratory tract.
May cause sensitization by inhalation.
|| Ingestion : Target Organs: Gastrointestinal tract
Symptoms: The most common side effects are:, Nausea,
Vomiting, Abdominal pain, Diarrhea, liver function change,
blood effects

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cefalexin:

Ecotoxicology Assessment

|| Acute aquatic toxicity : Toxic effects cannot be excluded
|| Chronic aquatic toxicity : Toxic effects cannot be excluded

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

Endocrine disrupting properties

No data available

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/08/2025
4.0	05/09/2026	11474837-00005	Date of first issue: 11/26/2024

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

UN/ID No. : UN 3334
Proper shipping name : Aviation regulated liquid, n.o.s.
(Cefalexin)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

CA. DSL : not determined

AICS : not determined

CN IECSC : not determined

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/08/2025
4.0	05/09/2026	11474837-00005	Date of first issue: 11/26/2024

Canadian lists

No substances are subject to CEPA Section 84 Ministerial Conditions.

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 05/09/2026
Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/08/2025
4.0	05/09/2026	11474837-00005	Date of first issue: 11/26/2024

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8